Literature DB >> 23143169

Efficacy of PET-CT for predicting the malignant potential of gastrointestinal stromal tumors.

Kozo Yoshikawa1, Mitsuo Shimada, Nobuhiro Kurita, Hirohiko Sato, Takashi Iwata, Shinya Morimoto, Tomohiko Miyatani, Hideya Kashihara, Chie Takasu, Noriko Matsumoto.   

Abstract

PURPOSES: Gastrointestinal stromal tumor (GIST) is the most common sarcoma of the intestinal tract. The risk category is usually determined by tumor size and mitotic count, but accurate preoperative diagnosis of GIST is very difficult. The purpose of this study is to evaluate the efficacy of positron emission tomography (PET)-CT for predicting the malignant potential of gastrointestinal stromal tumors.
METHODS: Ten patients with GIST who underwent a preoperative PET-CT examination were divided into two groups by risk category, and various factors were compared between the two groups. The relationships between the maximum standardized uptake value (SUVmax) and GIST parameters were examined.
RESULTS: Patients were classified into two groups by their risk category: (low/intermediate-risk or high-risk). The SUVmax was significantly higher in the high-risk group (11.0 ± 3.04) than in the low/intermediate-risk group (2.1 ± 1.5). The Ki67 labeling index was also significantly higher in the high-risk group (8.63 ± 6.2) than in the low/intermediate-risk group (1.75 ± 0.52). There was a significant correlation between the Ki67 labeling index and the SUVmax (p = 0.028) and between the mitotic index and the SUVmax (p = 0.029).
CONCLUSIONS: PET-CT can predict malignant potential. Cases with a SUVmax of over 5 may have malignant potential.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23143169     DOI: 10.1007/s00595-012-0411-6

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  26 in total

1.  Secondary resistance of extra-gastrointestinal stromal tumors to imatinib mesylate: report of a case.

Authors:  Koji Ando; Eiji Oki; Masahiko Sugiyama; Yan Zhao; Aya Kojima; Hidetaka Yamamoto; Yoichi Yamashita; Hiroshi Saeki; Akinobu Taketomi; Masaru Morita; Yoshihiro Kakeji; Shunichi Tsujitani; Yoshihiko Maehara
Journal:  Surg Today       Date:  2011-08-26       Impact factor: 2.549

2.  Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).

Authors:  Ronald P Dematteo; Jason S Gold; Lisa Saran; Mithat Gönen; Kui Hin Liau; Robert G Maki; Samuel Singer; Peter Besmer; Murray F Brennan; Cristina R Antonescu
Journal:  Cancer       Date:  2008-02-01       Impact factor: 6.860

3.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Authors:  Charles D Blanke; Cathryn Rankin; George D Demetri; Christopher W Ryan; Margaret von Mehren; Robert S Benjamin; A Kevin Raymond; Vivien H C Bramwell; Laurence H Baker; Robert G Maki; Michael Tanaka; J Randolph Hecht; Michael C Heinrich; Christopher D M Fletcher; John J Crowley; Ernest C Borden
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

4.  Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

Authors:  Charles D Blanke; George D Demetri; Margaret von Mehren; Michael C Heinrich; Burton Eisenberg; Jonathan A Fletcher; Christopher L Corless; Christopher D M Fletcher; Peter J Roberts; Daniela Heinz; Elisabeth Wehre; Zariana Nikolova; Heikki Joensuu
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

5.  Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach.

Authors:  N A C S Wong; R Young; R D G Malcomson; A G Nayar; L A Jamieson; V E Save; F A Carey; D H Brewster; C Han; A Al-Nafussi
Journal:  Histopathology       Date:  2003-08       Impact factor: 5.087

Review 6.  Diagnosis of gastrointestinal stromal tumors: A consensus approach.

Authors:  Christopher D M Fletcher; Jules J Berman; Christopher Corless; Fred Gorstein; Jerzy Lasota; B Jack Longley; Markku Miettinen; Timothy J O'Leary; Helen Remotti; Brian P Rubin; Barry Shmookler; Leslie H Sobin; Sharon W Weiss
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

7.  Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver.

Authors:  J V Vitola; D Delbeke; M P Sandler; M G Campbell; T A Powers; J K Wright; W C Chapman; C W Pinson
Journal:  Am J Surg       Date:  1996-01       Impact factor: 2.565

8.  Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread.

Authors:  Guy J C Burkill; Mohammed Badran; Omar Al-Muderis; J Meirion Thomas; Ian R Judson; Cyril Fisher; Eleanor C Moskovic
Journal:  Radiology       Date:  2003-02       Impact factor: 11.105

9.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

Review 10.  Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).

Authors:  George D Demetri
Journal:  Eur J Cancer       Date:  2002-09       Impact factor: 9.162

View more
  16 in total

1.  Imaging findings of primary malignant gastrointestinal stromal tumor of the liver.

Authors:  Hyun Ok Kim; Ji Eun Kim; Kyung Soo Bae; Bong Hoi Choi; Chi Young Jeong; Jong Sil Lee
Journal:  Jpn J Radiol       Date:  2014-03-29       Impact factor: 2.374

2.  Single-port laparoscopic and endoscopic cooperative surgery for a gastric gastrointestinal stromal tumor: report of a case.

Authors:  Toru Obuchi; Akira Sasaki; Shigeaki Baba; Hiroyuki Nitta; Koki Otsuka; Go Wakabayashi
Journal:  Surg Today       Date:  2014-03-16       Impact factor: 2.549

3.  Prediction of sentinel lymph node status using single-photon emission computed tomography (SPECT)/computed tomography (CT) imaging of breast cancer.

Authors:  Mai Tomiguchi; Mutsuko Yamamoto-Ibusuki; Yutaka Yamamoto; Mamiko Fujisue; Shinya Shiraishi; Touko Inao; Kei-ichi Murakami; Yumi Honda; Yasuyuki Yamashita; Ken-ichi Iyama; Hirotaka Iwase
Journal:  Surg Today       Date:  2015-04-19       Impact factor: 2.549

4.  Limited resections for duodenal gastrointestinal stromal tumors and their oncologic outcomes.

Authors:  Jun Chul Chung; Hyung Chul Kim; Sung Mo Hur
Journal:  Surg Today       Date:  2015-04-10       Impact factor: 2.549

Review 5.  Gastrointestinal autonomic nerve tumors: a clinical review.

Authors:  Abdul-Wahed N Meshikhes; Sami A Al-Momen
Journal:  J Gastrointest Surg       Date:  2015-03-25       Impact factor: 3.452

6.  Value of 18F-FDG PET/CT for differentiating diagnosis between malignant and benign primary gastric gastrointestinal mesenchymal tumors: a single-center retrospective study.

Authors:  Shengxu Li; Duanyu Lin; Mingdeng Tang; Daojia Liu; Qinghu Lyu; Jieping Zhang
Journal:  J Gastrointest Oncol       Date:  2022-04

7.  [Importance of PET for surgery of gastrointestinal stromal tumors].

Authors:  U Ronellenfitsch; B Wängler; S Niedermoser; A Dimitrakopoulou-Strauss; P Hohenberger
Journal:  Chirurg       Date:  2014-06       Impact factor: 0.955

8.  The Impact of Imatinib on Survival and Treatment Trends for Small Bowel and Colorectal Gastrointestinal Stromal Tumors.

Authors:  Hamda Almaazmi; Miloslawa Stem; Brian D Lo; James P Taylor; Sandy H Fang; Bashar Safar; Jonathan E Efron; Chady Atallah
Journal:  J Gastrointest Surg       Date:  2019-08-06       Impact factor: 3.452

9.  Correlation between the Uptake of 18F-Fluorodeoxyglucose (18F-FDG) and the Expression of Proliferation-Associated Antigen Ki-67 in Cancer Patients: A Meta-Analysis.

Authors:  Sheng-Ming Deng; Wei Zhang; Bin Zhang; Yin-Yin Chen; Ji-Hui Li; Yi-Wei Wu
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

10.  MRI-Based Radiomics Models for Predicting Risk Classification of Gastrointestinal Stromal Tumors.

Authors:  Haijia Mao; Bingqian Zhang; Mingyue Zou; Yanan Huang; Liming Yang; Cheng Wang; PeiPei Pang; Zhenhua Zhao
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.